Dialysis Market Surges Towards USD 198.2 Billion by 2033 | Driven by Rising Demand for Renal Replacement Therapy Solutions
06 févr. 2024 04h42 HE
|
Market.Us
New York, Feb. 06, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Dialysis Market value is projected to exceed USD 198.2 Billion by 2033, with a projected CAGR of 5.5% from 2024 to 2033. The...
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
23 janv. 2024 07h03 HE
|
Unicycive Therapeutics, Inc.
– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive...
Renal function test market forecasting a US$1.6 billion illumination by 2030, with Persistence Market Research
22 janv. 2024 02h00 HE
|
Persistence Market Research
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Renal Function Test Market: A Comprehensive Analysis Renal Function Tests are a series of diagnostic tests used to assess the functioning of the kidneys....
Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
18 janv. 2024 10h45 HE
|
Spherix Global Insights
Exton, PA, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Colleagues from Spherix Global Insights partnered with Cheeriodicals to assemble and deliver care packages to dialysis patients at local dialysis clinics...
Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
03 janv. 2024 16h13 HE
|
Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Since 2019, audited records of chronic kidney disease (CKD) non-dialysis patients has revealed an ongoing, annual uptick in the proportion of...
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
18 déc. 2023 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Global Genitourinary Collaboration and Licensing Agreement Analysis Report 2023: Breakdown by Company A-Z, Therapy Focus and Technology Type and Access to Upfront, Milestone, Royalties Data
17 nov. 2023 06h03 HE
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Genitourinary Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Genitourinary Collaboration and...
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
23 oct. 2023 07h03 HE
|
Unicycive Therapeutics, Inc.
- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology...
US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
13 oct. 2023 14h24 HE
|
Spherix Global Insights
Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have...
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
29 août 2023 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...